AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Insider Transactions Reported | Genprex(GNPX)saw insider trading activity on 7/1/2025
ByAinvest
Tuesday, Jul 1, 2025 6:00 pm ET1min read
Genprex(GNPX) saw insider trading activity on 7/1/2025, there were 2 insider trades during the day.
【History Insider Transaction】
| Declare date | Position | Name | Buy/Sell | Quantity | Price per share/USD | Total Amount/USD |
|---|---|---|---|---|---|---|
| 7/1/2025 | President, CEO and CFO | Confer Ryan M. | Sell | 5775 | 0.23 | 1.32k |
| 7/1/2025 | Chief Medical Officer | Berger Mark Stanley | Sell | 4500 | 0.23 | 1.03k |
| 2/19/2025 | Chief Medical Officer | Berger Mark Stanley | Sell | 585 | 0.41 | 0.24k |
| 2/19/2025 | President, CEO and CFO | Confer Ryan M. | Sell | 395 | 0.41 | 0.16k |
| 2/21/2024 | Chairman, President and CEO | Varner John Rodney | Sell | 2642 | 4.40 | 11.62k |
| 2/21/2024 | Chief Medical Officer | Berger Mark Stanley | Sell | 1319 | 4.40 | 5.8k |
| 2/21/2024 | Chief Financial Officer | Confer Ryan M. | Sell | 1126 | 4.40 | 4.95k |
| 4/24/2023 | EVP GC Chief Strategy Officer | VACZY CATHERINE M | Buy | 20000 | 1.07 | 21.48k |
| 4/24/2023 | Chairman, President and CEO | Varner John Rodney | Buy | 19000 | 1.06 | 20.05k |
| 8/1/2022 | Chief Financial Officer | Confer Ryan M. | Buy | 116973 | 0.02 | 1.75k |
[Company Profile]
Genprex, Inc. was incorporated in Delaware in April 2009. The company is a privately held, clinical-stage biopharmaceutical company developing immunogene therapies for cancer. Genprex is a clinical stage gene therapy company developing a new approach to treating cancer, based upon their novel proprietary technology platform, including their initial product candidate, Oncoprex immunogene therapy, or Oncoprex. Their platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet